Skip to main content

Third Rock Ventures — Portfolio, Page 2

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

50
Companies
$6.1B
Total invested
$136.5M
Avg. check
19
Industries
Biotechnology 21Health Care 14Therapeutics 11Medical 9Pharmaceutical 5Medical Device 4+13 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 2548 of 50
Cedilla Therapeutics
October 2021

Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.

Biotechnology · Cambridge$25.0M Series B
Casma Therapeutics
March 2026

Casma Therapeutics is a biotechnology company harnessing the natural cellular process of autophagy to design new medicines.

Biotechnology · Cambridge$7.6M Grant
Syremis Therapeutics
December 2025

Syremis Therapeutics is developing novel medicines to make a profound impact on the treatment of mental health disorders.

Health Care · Tel Aviv$165.0M Series A
Azalea Therapeutics
November 2025

Azalea Therapeutics is a biotechnology company with a primary focus on developing cancer immunotherapies.

Biotechnology · Berkeley$65.0M Series A
ARTBIO
July 2025

ARTBIO is a clinical-stage radiopharmaceutical biotechnology business that is working to create a new class of alpha radioligand medicines.

Biotechnology · Cambridge$132.0M Series B
Rhythm Pharmaceuticals
July 2025

Rhythm is a biopharmaceutical company focused on developing and commercializing peptide therapeutics

Biotechnology · Boston$175.0M Post Ipo Equity
Merida Biosciences
April 2025

Merida Biosciences is a biotech company focused on developing precision treatments, particularly for autoimmune diseases.

Biotechnology · Cambridge$121.0M Series A
Trace Neuroscience
November 2024

Trace Neuroscience is a biopharmaceutical company that aims to extend the promise of genetic medicine to patients.

Biotechnology · South San Francisco$101.0M Series A
Red Arrow Therapeutics
September 2024

Red Arrow Therapeutics is a biotech firm that provides systemic cytokine delivery, targeted intratumoral activation, and biological potency.

Alternative Medicine · Minato$55.0M Series A
Marea Therapeutics
June 2024

Marea is a biotechnology company that develops therapies and medications for the treatment of cardioendocrine illness patients.

Biotechnology · San Francisco$190.0M Series B
Clasp Therapeutics
March 2024

Clasp Therapeutics offers to reach of immuno-oncology with novel precision medicines that enable the immune system.

Biotechnology · Cambridge$150.0M Series A
Synnovation Therapeutics
December 2023

Synnovation Therapeutics is a precision oncology company that develops therapeutics that aims to help people with cancer.

Biotechnology · Wilmington$102.0M Series A
Terremoto Biosciences
November 2023

Terremoto Biosciences is a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines.

Biotechnology · San Francisco$175.0M Series B
Pliant Therapeutics
January 2023

Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.

Biotechnology · South San Francisco$287.5M Post Ipo Equity
MOMA Therapeutics
May 2022

MOMA Therapeutics operates as a biotechnology company.

Biotechnology · Cambridge$150.0M Series B
Allena Pharmaceuticals
May 2022

Allena Pharmaceuticals develops and commercializes non-systemic protein therapeutics to treat metabolic and orphan diseases.

Biotechnology · Newton$2.8M Post Ipo Equity
Ambys Medicines
December 2021

Ambys Medicines is a biotechnology company focused on discovering and developing regenerative and restorative therapies.

Biotechnology · South San Francisco$47.0M Series A
SAGE Therapeutics
November 2020

SAGE Therapeutics develops and delivers novel medicines for most debilitating and disabling central nervous system disorders.

Biotechnology · Cambridge$650.0M Post Ipo Equity
Alcresta
February 2020

Alcresta develops enzyme-based nutritional products for infants and adults with acute and chronic diseases.

Biotechnology · Newton$10.0M Series Unknown
Sesen Bio
June 2018

Sesen Bio is focused on developing innovative protein-based therapeutics to improve human health and treat diseases.

Biotechnology · Cambridge$40.0M Post Ipo Equity
Rheos Medicines
March 2018

A biopharmaceutical company developing novel medicines that modulate metabolic pathways in immune cells to treat disease.

Biopharma · Cambridge$60.0M Series A
Cibiem, Inc.
October 2016

Cibiem, a medical device company, develops minimally invasive, catheter-based therapeutics for sympathetic nervous system-mediated diseases.

Health Care · Los AltosDebt Financing
Rhythm Metabolic
August 2015

Rhythm Metabolic develops a novel peptide MC4 agonist for the treatment of obesity caused by genetic deficiencies.

Developer Platform · Boston$40.0M Series A
Foundation Medicine
January 2013

Foundation medicine is a molecular information company developing clinical diagnostic tests that facilitates personalized cancer therapies.

Biotechnology · Cambridge$13.5M Series B

Where Third Rock Ventures invests

Biotechnology21
Health Care14
Therapeutics11
Medical9
Pharmaceutical5
Medical Device4

About Third Rock Ventures's portfolio

How many companies has Third Rock Ventures invested in?

Third Rock Ventures has invested in 50 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Third Rock Ventures invest in?

Third Rock Ventures's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Pharmaceutical. The firm invests across 19 different industry categories.

What is Third Rock Ventures's largest investment?

Among tracked funding rounds, SAGE Therapeutics received $650.0M in a Post Ipo Equity round. Third Rock Ventures's total known invested capital is $6.1B.

What is the average investment size for Third Rock Ventures?

Third Rock Ventures's average investment size is $136.5M across its portfolio of 50 companies.

What are Third Rock Ventures's most recent investments?

Recent Third Rock Ventures portfolio additions include Cedilla Therapeutics, Casma Therapeutics, Syremis Therapeutics, Azalea Therapeutics, ARTBIO. These companies were founded in 2020 or later.

Reach the founders behind these 50 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →